Daily Endocrinology Research Analysis
Analyzed 132 papers and selected 3 impactful papers.
Summary
Analyzed 132 papers and selected 3 impactful articles.
Selected Articles
1. Brown fat protects against hepatic oxidative stress by remodeling the circulating metabolome.
Multi-omics across BAT-ablated mice and humans revealed that BAT shapes the circulating metabolome, clearing BCAAs and triglycerides and producing a cold-inducible metabolite, 3-hydroxystearic acid (3-OHSA). 3-OHSA serves as a readout of BAT activation and directly lowers hepatic mitochondrial membrane potential and ROS, limiting oxidative stress and defining a BAT–liver protective axis.
Impact: This study identifies a specific BAT-derived metabolite with mechanistic action on the liver, reframing BAT as an endocrine organ with therapeutic and biomarker potential for metabolic liver disease.
Clinical Implications: 3-OHSA could serve as a biomarker of BAT activation and a lead for hepatoprotective therapies targeting oxidative stress. Strategies that augment BAT activity or leverage 3-OHSA biology may complement MASLD and metabolic syndrome management.
Key Findings
- Integrated metabolomics/lipidomics across BAT-ablated mice and human cohorts defined BAT-linked circulating molecular signatures.
- BAT activity supports clearance of circulating branched-chain amino acids and triglycerides.
- Identification of a cold-inducible BAT-derived metabolite, 3-hydroxystearic acid (3-OHSA), detectable in circulation.
- 3-OHSA reduces hepatic mitochondrial membrane potential and reactive oxygen species, limiting oxidative stress.
Methodological Strengths
- Cross-species, multi-compartment integration (serum, tissues, extracellular fluids, conditioned media).
- Functional validation linking a specific metabolite (3-OHSA) to hepatic mitochondrial and ROS effects.
Limitations
- Predominantly preclinical; causal relevance and pharmacokinetics of 3-OHSA in humans remain to be established.
- Magnitude and durability of effects under diverse metabolic states were not fully defined.
Future Directions: Validate 3-OHSA as a biomarker in clinical cohorts; delineate its receptor/targets and safety; test BAT-activating or 3-OHSA–mimetic interventions in MASLD and cardiometabolic disease.
Brown adipose tissue (BAT) regulates systemic metabolism beyond thermogenesis, yet the circulating mediators through which BAT communicates with other organs remain less explored. Here, we performed comprehensive serum metabolomics and lipidomics in BAT-ablated mice and human cohorts with varying BAT activity to delineate how BAT activity shapes the circulating metabolome. By integrating datasets across serum, tissues, extracellular fluids, and conditioned media, we assembled BAT-linked circulating molecular signatures.
2. Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy.
Adolescents with obesity exhibited higher serum BCAAs but lower BCKAs versus healthy-weight peers, a pattern distinct from adults and modified by sex/age. Microbiome composition and functional potential differed despite similar diversity, and FMT into germ-free mice linked specific taxa to weight gain. Longitudinal features correlated with health changes during intervention.
Impact: Defines adolescent-specific metabolic and microbial signatures, cautioning against extrapolating adult biomarkers to youth and informing age-tailored obesity interventions.
Clinical Implications: BCAA/BCKA and microbiome profiles in adolescents may refine risk stratification and monitoring during lifestyle or pharmacologic obesity treatments; FMT findings nominate taxa for mechanistic and therapeutic targeting.
Key Findings
- Adolescents with obesity had higher circulating BCAAs but lower BCKAs compared with healthy-weight controls, differing from adult obesity patterns.
- Microbiome diversity was similar across groups, but membership and functional potential differed; specific taxa associated with weight gain in FMT recipients.
- Longitudinal metabolic and microbial features correlated with clinical changes during a 6-month intervention.
Methodological Strengths
- Prospective longitudinal cohort integrating targeted serum metabolomics and stool microbiome profiling.
- Functional fecal microbiota transplantation into germ-free mice to probe causality.
Limitations
- Observational design limits causal inference; detailed FMT donor–recipient sample sizes and durability beyond 6 months are not fully delineated.
- Generalizability across diverse ethnicities and treatment modalities requires external validation.
Future Directions: Validate adolescent-specific biomarkers across populations, map diet–microbe–host axes, and test microbiome-targeted or amino acid–modulating interventions with clinical endpoints.
BACKGROUNDObesity and weight loss in adults have been associated with distinct metabolome and gut microbiome features, but the extent to which those associations apply to adolescent stages remain unclear.METHODSThe Pediatric Obesity Microbiome and Metabolism Study (POMMS) enrolled 220 adolescents aged 10-18 with severe obesity (OB) and 67 individuals who were healthy weight controls (HWCs). Blood, stool, and clinical measures were collected at baseline and after a 6-month obesity interv
3. A controlled-release mitochondrial protonophore attenuates early- and late-stage atheroprogression in mice.
An oral controlled-release mitochondrial protonophore (CRMP, formulated 2,4-dinitrophenol) reduced atherogenesis in LDLR-deficient mice on a high-fat, cholesterol diet, extending prior evidence that CRMP reverses dyslipidemia, steatosis, and insulin resistance in rodents and nonhuman primates. These data support mitochondrial uncoupling as a translatable strategy for cardiometabolic disease.
Impact: Provides preclinical proof that controlled mitochondrial uncoupling can attenuate atheroprogression in insulin-resistant settings, reviving a historically potent mechanism via safer pharmacology.
Clinical Implications: If translated, CRMP-like agents could target residual ASCVD risk in insulin resistance by improving hepatic lipid handling and vascular disease concurrently; safety and dose optimization will be paramount.
Key Findings
- Oral controlled-release 2,4-dinitrophenol (CRMP) attenuated both early- and late-stage atheroprogression in LDLR-deficient mice on an HFCD.
- Builds on prior cross-species data that CRMP reverses hypertriglyceridemia, hepatic steatosis, and insulin resistance.
- Supports mitochondrial uncoupling as a therapeutic approach for cardiometabolic disease.
Methodological Strengths
- Therapeutic testing in a genetically susceptible murine model of cardiometabolic atherogenesis.
- Convergence with prior efficacy and safety signals across rodents and nonhuman primates.
Limitations
- Preclinical murine data; human efficacy, long-term safety, and dose-response remain unknown.
- Mechanistic dissection of plaque biology and off-target effects is limited in the abstract.
Future Directions: Proceed to GLP toxicology, PK/PD, and early-phase human studies; define vascular and hepatic mechanistic endpoints and biomarkers to guide dose and safety.
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality in patients with insulin resistance, and new therapies are urgently needed. We previously developed an orally administered formulation of 2,4-dinitrophenol, here termed controlled-release mitochondrial protonophore (CRMP), and showed that it safely reversed hypertriglyceridemia, hepatic steatosis, and insulin resistance in dysmetabolic rodents and nonhuman primates. Here, we investigated the thera